Pierre Fabre STX-241 (SILVER)https://www.nct-dresden.de/en/trials/900-000002384https://www.nct-dresden.de/@@site-logo/logo-nct.svg
Pierre Fabre STX-241 (SILVER)
Thoracic tumors
Non-small cell lung cancer (NSCLC)
other systemic therapies
The goal of this First-In-Human (FIH) Phase I/II trial is to establish the safetyprofile, determine the Recommended Phase II Dose (RP2D), explore the pharmacokinetic (PK)exposure and pharmacodynamic (PD) properties as well as assess the efficacy of STX-241, amutant selective Central Nervous System (CNS)-penetrant fourth generation EGFR TKI, inparticipants with locally advanced or metastatic NSCLC that progressed during orfollowing third generation EGFR TKI such as osimertinib due to C797X double acquired(secondary) mutations.
The goal of this First-In-Human (FIH) Phase I/II trial is to establish the safetyprofile, determine the Recommended Phase II Dose (RP2D), explore the pharmacokinetic (PK)exposure and pharmacodynamic (PD) properties as well as assess the efficacy of STX-241, amutant selective Central Nervous System (CNS)-penetrant fourth generation EGFR TKI, inparticipants with locally advanced or metastatic NSCLC that progressed during orfollowing third generation EGFR TKI such as osimertinib due to C797X double acquired(secondary) mutations.
